![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
TURQUOISE-I Part 1b: Ombitasvir/Paritaprevir/r +
Dasabuvir + RBV for HCV/HIV Co-Infection
|
|
|
Reported by Jules Levin
CROI 2016 Feb 22-24 Boston
David Wyles1, Michael Saag2, Roger Trinh3, Jacob Lalezari4, Oluwatoyin Adeyemi5, Laveeza Bhatti 6, Amit Khatri3, Jennifer R King3, Yiran B Hu3, Rolando Viani3, Nancy S Shulman3, Peter Ruane7
1University of California San Diego, La Jolla, California, United States; 2Center for AIDS Research, University of Alabama at Birmingham, Birmingham, Alabama, United States; 3AbbVie Inc., North Chicago, Illinois, United States; 4Quest Clinical Research, San Francisco, California, United States; 5Ruth M Rothstein CORE Center, Chicago, Illinois, United States; 6AIDS Healthcare Foundation, Beverly Hills, California, United States; 7Ruane Medical & Liver Health Insti tute, Los Angeles, California, United States
![CROI1](../images/030516/030516-6/CROI1.gif)
![CROI2](../images/030516/030516-6/CROI2.gif)
![CROI3](../images/030516/030516-6/CROI3.gif)
![CROI4](../images/030516/030516-6/CROI4.gif)
![CROI5](../images/030516/030516-6/CROI5.gif)
![CROI6](../images/030516/030516-6/CROI6.gif)
![CROI7](../images/030516/030516-6/CROI7.gif)
![CROI8](../images/030516/030516-6/CROI8.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|